SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Manuel Jaime as its new Senior Vice President, Technology and Digital Health. Jaime will lead all activities related to information technology, data management and security, data analytics, and mobile/connected health solutions.
“Globalization of our data management applications, development of robust connected health solutions, and maintaining the security of customer and company data are key to our ability to provide a revolutionary customer experience to our growing customer base and distribution partners worldwide,” said Kim Blickenstaff, president and CEO of Tandem Diabetes Care. “Manuel has been a pioneer in these areas, with broad-based experience that we believe will enhance our customer offerings, improve internal efficiencies and help further establish our position as a leader in digital health in the diabetes community.”
“Leveraging leading edge technologies to deliver exceptional customer experiences has been a focus throughout my career, which aligns well with Tandem’s vision and philosophy,” said Jaime. “What Tandem has accomplished in such a short period of time for people impacted by type 1 diabetes is incredible. I look forward to applying my technology expertise to help take these efforts to the next level.”
Jaime is an accomplished technology executive with more than 20 years of experience in incubating and commercializing emerging products and services in the high-tech industry. He has spearheaded technology development, product management, and technology strategy and planning at startups and established companies. Jaime was most recently Chief Technology Officer at Cedar Electronics, a leader in the field of driver awareness, communications and information systems. He was also a co-founder and Chief Executive Officer of ClipCast Technologies, and he previously held various roles at CardioNet and Qualcomm. He also is an inventor on more than 20 patents relating to connected devices, wireless systems, video platforms, and low-power radio frequency. Jamie is a graduate of the Leaders for Global Operations (LGO) Program at the Massachusetts Institute of Technology (MIT) Sloan School of Management where he received an MBA and a MS in Mechanical Engineering. He also holds a BS in Mechanical Engineering and a MS in Systems Engineering from MIT.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.
Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
Forward Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements relate to, among other things, the anticipated future growth of the Company and the Company’s goals to enhance product offerings, improve internal efficiencies and be leader in digital health in the diabetes community. These statements are subject to numerous risks and uncertainties, including our ability to obtain regulatory approval for new products and products under development and the timing of any such approvals; market acceptance of the Company’s existing products and products under development by physicians and people with diabetes; the Company’s ability to establish and sustain operations to support international sales; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; as well as other risks identified in our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and other documents that we file with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.